5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.07▼ | 1.05▲ | 1.05▲ | 1.02▲ | 0.95▲ |
MA10 | 1.06▼ | 1.06▼ | 1.07▼ | 0.98▲ | 1.00▲ |
MA20 | 1.08▼ | 1.07▼ | 1.05▼ | 0.95▲ | 0.96▲ |
MA50 | 1.07▼ | 1.00▲ | 1.01▲ | 0.97▲ | 1.26▼ |
MA100 | 1.02▲ | 1.06▼ | 1.03▲ | 0.96▲ | 1.67▼ |
MA200 | 1.08▼ | 1.00▲ | 0.99▲ | 1.10▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.006▼ | -0.002▼ | 0.016▲ | 0.026▲ |
RSI | 45.840▼ | 49.884▼ | 51.207▲ | 56.711▲ | 49.933▼ |
STOCH | 45.646 | 18.071▼ | 18.071▼ | 49.067 | 15.454▼ |
WILL %R | -72.123 | -72.123 | -72.123 | -56.818 | -75.893▼ |
CCI | -20.860 | -55.949 | -63.017 | 119.883▲ | 63.450 |
Wednesday, May 15, 2024 10:41 AM
The firm’s stock price fluctuated 20.42% within the last five trades and 23.28% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the ...
|
Wednesday, May 15, 2024 05:17 AM
This funding will be dedicated to support the rapid advancement of MiNK-215, our innovative CAR iNKT Cell Therapy targeting fibroblast activation protein or FAP solid tumors. MiNK-215 is our lead ...
|
Wednesday, May 15, 2024 12:04 AM
Discover how MiNK Therapeutics Inc navigates financial challenges and advances key clinical programs amidst strategic operational adjustments.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 1.08 | 1.08 | 1.045 | 1.05 | 70,038 |
15/05/24 | 1.09 | 1.30 | 0.9311 | 1.04 | 560,216 |
14/05/24 | 0.97 | 1.16 | 0.97 | 1.12 | 633,700 |
13/05/24 | 1.01 | 1.04 | 0.95 | 0.9874 | 4,557,687 |
10/05/24 | 0.92 | 0.92 | 0.89 | 0.90 | 20,100 |
09/05/24 | 0.93 | 0.93 | 0.86 | 0.8993 | 135,759 |
08/05/24 | 0.93 | 0.9517 | 0.92 | 0.93 | 18,987 |
07/05/24 | 0.9405 | 0.9774 | 0.9235 | 0.9301 | 58,845 |
06/05/24 | 0.98 | 1.01 | 0.9405 | 0.9407 | 119,485 |
03/05/24 | 0.99 | 0.99 | 0.94 | 0.98 | 29,534 |
|
|
||||
|
|
||||
|
|